Navigation Links
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo

ote Regarding Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as, but not limited to, "suggest," "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "may," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of iloperidone or Vanda's other product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for iloperidone or the company's other product candidates, a lack of acceptance of iloperidone or Vanda's other product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended March 31, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

CONTACT: Chip Clark of Vanda Pharmaceuticals Inc., +1-240-599-4500, chip.clark@vandapharma.com

We
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:3/26/2015)... , March 26, 2015 Zimmer Holdings, Inc. ... new mobile app designed to serve as a feature-rich resource ... product. For those experiencing knee pain, the ... about the causes of knee pain and helps them understand ... a safe and simple non-surgical treatment option. For those who ...
(Date:3/26/2015)... , March 26, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... received a patent acceptance notice from the Israeli patent ... to prevent or reduce tissue damage caused by an ... when cardiac vessels are opened after a blockage causing ... stroke victims. Damage can be caused to ...
(Date:3/26/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a leading ... healthcare industry in the United States ... secured a new $45.0 million credit facility with JPMorgan Chase ... facility with its prior lender group.  Effective ... senior secured credit agreement comprised of a $10.0 million asset-based ...
Breaking Medicine Technology:Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 2InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 4
... NEW YORK, Feb. 15, 2011 Reportlinker.com ... is available in its catalogue: ... CE countries 2011 - Comparative analysis, reimbursement ... http://www.reportlinker.com/p0395681/Generic-and-innovative-drug-market-in-CE-countries-2011---Comparative-analysis-reimbursement-policies-and-development-forecasts-for-2011-2013 ...
... 15, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... a conference call and a live Internet webcast along with ... a.m. ET (7:00 a.m. PT) to discuss results for the ... number to participate on this call is (877) 295-5743, confirmation ...
Cached Medicine Technology:Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013 2Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:3/26/2015)... (PRWEB) March 26, 2015 The American College ... be on the topics of the DAOM Program as well ... Program Overview Webinar will be hosted by Dr. Carla Wilson, ... the next steps on how to prepare for the spring ... March 25, March 27, April 1 and April 3. Attendees ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Baruch ... new team of nationally renowned scientists to focus exclusively ... a move that nearly triples its research capacity and ... solely on hepatitis B and liver cancer in the ... Block, Jinhong Chang, Ju Tao Guo and Ying-Hsiu Su ...
(Date:3/26/2015)... 26, 2015 Visiting Nurse Association ... 18th annual gala fundraiser, Lighting the Way, Brightening the ... at The Madison Hotel in Morristown, NJ. , ... by renowned musician Rio Clemente, delightful cuisine, an extensive ... Dave Hertzel. Additionally, two prestigious awards will be presented ...
(Date:3/26/2015)... NY (PRWEB) March 26, 2015 ... its 30th “Introduction to Hyperbaric Medicine” course, which ... Medical Society (UHMS) and the National Board of ... provides the 40-hour course 4 times a year ... around the NY tri-state region; registration is available ...
(Date:3/26/2015)... March 26, 2015 On March 5, ... Matthews is out for the season with a torn ... while the Trail Blazers were competing against Dallas, and ... specialist, Izzy Silva, M.D., who has treated many ... and whether it could be prevented. , "Part ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming Webinars 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 3Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 4Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4
... the U.S. Department of Agriculture found that a compound in ... compound, pterostilbene, is a potent antioxidant that could be developed ... effects than some commercial drugs that are currently used to ... cause of cancer death in the United States. ...
... discovered by researchers at Weill Cornell Medical College could prove ... ,The compound, called SS31, is able to cross the ... to stroke-related tissue damage. ,"In our experiments, we ... stroke led to a much smaller area of brain tissue ...
... specially developed proteins could make our bodies more resistant ... ,Steaks and chicken fillets laced with some ... against oxidation – oxidation is considered a major cause ... Shchepinov, a former Oxford University scientist, has found ...
... University of Wisconsin-Madison claim that they can efficiently seek ... cells//. This is very similar to the Nature's way ... ,The new tumor targeting strategy, presented today (March ... Chemical Society, cleverly harnesses one of the body's natural ...
... wisdom, in order to deal with teenage pregnancies and ... ,Improving pupil-teacher relationships and raising a teenager’s self-confidence ... will do the trick, say the researchers. In this ... newer ones such as focusing on sexual risks ,and ...
... the omega-3 fatty acids docosahexaenoic acid (DHA) successfully reduced ... trial, backing up previous results with higher doses. // ... which is likely to be of clinical significance with ... subjects," wrote lead author Hannah Theobald from King's College ...
Cached Medicine News:Health News:Eat Berries, Prevent Colon Cancer 2Health News:Eat Berries, Prevent Colon Cancer 3Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Tumors Targeted Naturally 2Health News:Tumors Targeted Naturally 3Health News:'School Sermons' Need a Comeback 2Health News:Low-dose Omega-3 Linked to Lower Blood Pressure 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: